{"id":326,"date":"2009-10-01T00:00:00","date_gmt":"2009-09-30T23:00:00","guid":{"rendered":"http:\/\/inmunologia.webs.uvigo.es\/?post_type=jetpack-portfolio&#038;p=326"},"modified":"2018-06-13T14:37:41","modified_gmt":"2018-06-13T13:37:41","slug":"health-impact-of-engineered-metal-oxide-nanoparticles","status":"publish","type":"jetpack-portfolio","link":"https:\/\/inmunologia.webs9.uvigo.es\/?portfolio=health-impact-of-engineered-metal-oxide-nanoparticles","title":{"rendered":"Health Impact of Engineered Metal and Metal Oxide Nanoparticles: Response, Bioimaging and Distribution at Cellular and Body Level (HINAMOX)"},"content":{"rendered":"<p>Reference: FP7-NMP-2008-SMALL-2. Project ID:\u00a0228825<br \/>\nFunding Entity: European Commission<br \/>\nCoordinator: Sergio Moya (CIC biomaGUNE)<br \/>\nPrincipal Investigator: <a href=\"http:\/\/inmunologia.webs.uvigo.es\/members\/africa-gonzalez-fernandez\/\">Dr. \u00c1frica Gonz\u00e1lez-Fern\u00e1ndez<\/a> (WP6 leader)<br \/>\nDuration: 01\/10\/2009 &#8211; 30\/09\/2012<\/p>\n<p>Working group:<\/p>\n<p><a href=\"http:\/\/inmunologia.webs.uvigo.es\/members\/rosana-simon-vazquez\/\">Dr. Rosana Sim\u00f3n V\u00e1zquez<\/a><br \/>\n<a href=\"http:\/\/inmunologia.webs.uvigo.es\/members\/maria-elina-garet-fernandez\/\">Dr. Mar\u00eda Elina Garet Fern\u00e1ndez<\/a><br \/>\n<a href=\"http:\/\/inmunologia.webs.uvigo.es\/members\/tamara-lozano-fernandez\/\">Dr. Tamara Lozano Fern\u00e1ndez<\/a><br \/>\nDr. Silvia Lorenzo Abalde\u00a0 (former member)<br \/>\nDr. Mercedes Peleteiro Olmedo\u00a0(former member)<br \/>\nDr. Bel\u00e9n D\u00edaz Freitas (former member)<\/p>\n<p>Summary:<\/p>\n<p>The objective of HINAMOX was to understand the safety and human health implications of metal oxide nanoparticles (NPs). This understanding is required both for future assessments of the safety of nano-based products, and to achieve greater public acceptance of nanotechnology and public awareness of the overall benefits that nanotechnology can bring. This is a strong prerequisite for the future successful development and benefit of nanotechnology products.<\/p>\n<p>In this project, the Immunology Group studied the effects of the interaction of the immune system with the metal oxide NPs by means of <em>in vitro<\/em> cytotoxicity assays and <em>in vivo<\/em> assays, such as the T-dependent antibody response (TDAR) among others.<\/p>\n<p><strong>Read more in:\u00a0 <\/strong><\/p>\n<p><strong>\u00a0\u00a0<\/strong><a href=\"https:\/\/cordis.europa.eu\/project\/rcn\/92651_en.html\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-1400 alignnone\" src=\"http:\/\/inmunologia.webs.uvigo.es\/wp-content\/uploads\/2009\/10\/Hinamox-2-300x205.png\" alt=\"\" width=\"300\" height=\"205\" srcset=\"https:\/\/inmunologia.webs9.uvigo.es\/wp-content\/uploads\/2009\/10\/Hinamox-2-300x205.png 300w, https:\/\/inmunologia.webs9.uvigo.es\/wp-content\/uploads\/2009\/10\/Hinamox-2.png 332w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reference: <strong>HINAMOX 228825<\/strong><br \/>\nFunding Entity: U.E. 7\u00ba Programa marco<br \/>\nCoordinator: Sergio Moya (CIC biomaGUNE)<br \/>\nPI: Dr. \u00c1frica Gonz\u00e1lez-Fern\u00e1ndez. WP6 leader<br \/>\nDuration: 01\/10\/2009 &#8211; 30\/09\/2012 <span class=\"readmore\"><a href=\"https:\/\/inmunologia.webs9.uvigo.es\/?portfolio=health-impact-of-engineered-metal-oxide-nanoparticles\">Continue Reading<\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":1351,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"footnotes":""},"jetpack-portfolio-type":[10,22],"jetpack-portfolio-tag":[31,26],"class_list":["post-326","jetpack-portfolio","type-jetpack-portfolio","status-publish","format-standard","has-post-thumbnail","hentry","jetpack-portfolio-type-nanomedicine","jetpack-portfolio-type-projects","jetpack-portfolio-tag-european","jetpack-portfolio-tag-international"],"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/jetpack-portfolio\/326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/jetpack-portfolio"}],"about":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/types\/jetpack-portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=326"}],"version-history":[{"count":12,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/jetpack-portfolio\/326\/revisions"}],"predecessor-version":[{"id":1405,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/jetpack-portfolio\/326\/revisions\/1405"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/media\/1351"}],"wp:attachment":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=326"}],"wp:term":[{"taxonomy":"jetpack-portfolio-type","embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fjetpack-portfolio-type&post=326"},{"taxonomy":"jetpack-portfolio-tag","embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fjetpack-portfolio-tag&post=326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}